Pfizer Inc. (PFE)
Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript
Pfizer Inc. ( PFE ) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO David Denton - Executive VP & CFO Aamir Malik Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.
Pfizer reports strong Q3 earnings, raises full-year profit guidance
Pfizer Inc (NYSE:PFE, ETR:PFE) reported third quarter financial results that topped Wall Street expectations despite a year-over-year drop in earnings and sales, while raising its full-year profit guidance. The company reported Q3 revenue of $16.7 billion, slightly above analyst estimates of $16.55 billion, representing a 7% decline compared with the same period last year.
Here's What Key Metrics Tell Us About Pfizer (PFE) Q3 Earnings
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid
The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.
Pfizer's Q3 Earnings Beat on Top and Bottom Lines
Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected.
Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer
Metsera said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nordisk's new proposal values Metsera at up to $86.20 per share, for a total of around $10 billion.
Pfizer's revenue falls as COVID sales and vaccine recommendations continue to fade
The full-year outlook was lifted, but the stock lost ground.
Pfizer's Q3: Stagnation Continues
Pfizer reported another quarter of stagnation, with Q3 2025 revenue and EPS both declining year-over-year despite beating consensus estimates. PFE's revenue mix remains weak, with Primary Care sales dropping 15.6% and only Oncology showing growth ahead of inflation; management guidance remains largely unchanged. The forward P/E ratio is expected to stagnate, and low valuation multiples reflect poor growth prospects, making sector comparisons misleading.
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.06 per share a year ago.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025)
Shares of Pfizer ( NYSE: PFE ) lost 9.90% over the past month after gaining 10.02% the month prior.
Pfizer raises 2025 profit forecast for second time in a row
Pfizer lifted its full-year profit forecast for the second time in a row on Tuesday, buoyed by strong demand for its blockbuster heart treatment and blood thinner.
